{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:55:20Z","timestamp":1783608920022,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/aps.2016.119","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T09:02:29Z","timestamp":1477299749000},"page":"69-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation"],"prefix":"10.1038","volume":"38","author":[{"given":"Qiang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-ping","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-kui","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-yong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"BFaps2016119_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","volume":"63","author":"E Scorletti","year":"2015","unstructured":"Scorletti E, West AL, Bhatia L, Hoile SP, McCormick KG, Burdge GC, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. J Hepatol 2015; 63: 1476\u201383.","journal-title":"J Hepatol"},{"key":"BFaps2016119_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","volume":"59","author":"F Nascimbeni","year":"2013","unstructured":"Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859\u201371.","journal-title":"J Hepatol"},{"key":"BFaps2016119_CR3","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM . Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol 2015; 62: 1148\u201355.","journal-title":"J Hepatol"},{"key":"BFaps2016119_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/aps.2015.11","volume":"36","author":"L Gan","year":"2015","unstructured":"Gan L, Meng ZJ, Xiong RB, Guo JQ, Lu XC, Zheng ZW, et al. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice. Acta Pharmacol Sin 2015; 36: 597\u2013605.","journal-title":"Acta Pharmacol Sin"},{"key":"BFaps2016119_CR5","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","volume":"62","author":"V Ratziu","year":"2015","unstructured":"Ratziu V, Goodman Z, Sanyal A . Current efforts and trends in the treatment of NASH. J Hepatol 2015; 62: S65\u2013S75.","journal-title":"J Hepatol"},{"key":"BFaps2016119_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2012.10.030","volume":"58","author":"FJ Verdam","year":"2013","unstructured":"Verdam FJ, Dallinga JW, Driessen A, Jonge Cd, Moonen EJC, van Berkel JBN, et al. Non-alcoholic steatohepatitis: A non-invasive diagnosis by analysis of exhaled breath. J Hepatol 2013; 58: 543\u20138.","journal-title":"J Hepatol"},{"key":"BFaps2016119_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jceh.2015.06.004","volume":"5","author":"S Iyer","year":"2015","unstructured":"Iyer S, Upadhyay PK, Majumdar SS, Nagarajan P . Animal models correlating immune cells for the development of NAFLD\/NASH. J Clin Exp Hepatol 2015; 5: 239\u201345.","journal-title":"J Clin Exp Hepatol"},{"key":"BFaps2016119_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","volume":"81","author":"BM Forman","year":"1995","unstructured":"Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687\u201393.","journal-title":"Cell"},{"key":"BFaps2016119_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.phrs.2010.12.018","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Li F, Guo GL . Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol Res 2011; 63: 259\u201365.","journal-title":"Pharmacol Res"},{"key":"BFaps2016119_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1262-3636(08)74605-6","volume":"34","author":"B Cariou","year":"2008","unstructured":"Cariou B . The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab 2008; 34: 685\u201391.","journal-title":"Diabetes Metab"},{"key":"BFaps2016119_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/aps.2014.116","volume":"36","author":"Y Jiao","year":"2015","unstructured":"Jiao Y, Lu Y, Li XY . Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin 2015; 36: 44\u201350.","journal-title":"Acta Pharmacol Sin"},{"key":"BFaps2016119_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.taap.2013.06.016","volume":"272","author":"G Li","year":"2013","unstructured":"Li G, Kong B, Zhu Y, Zhan L, Williams JA, Tawfik O, et al. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol Appl Pharmacol 2013; 272: 299\u2013305.","journal-title":"Toxicol Appl Pharmacol"},{"key":"BFaps2016119_CR13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1172\/JCI21025","volume":"113","author":"M Watanabe","year":"2004","unstructured":"Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408\u201318.","journal-title":"J Clin Invest"},{"key":"BFaps2016119_CR14","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1210\/mend.15.10.0712","volume":"15","author":"HR Kast","year":"2001","unstructured":"Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15: 1720\u20138.","journal-title":"Mol Endocrinol"},{"key":"BFaps2016119_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","volume":"125","author":"T Claudel","year":"2003","unstructured":"Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003; 125: 544\u201355.","journal-title":"Gastroenterology"},{"key":"BFaps2016119_CR16","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45: 3569\u201372.","journal-title":"J Med Chem"},{"key":"BFaps2016119_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bbalip.2014.08.005","volume":"1851","author":"RM Gadaleta","year":"2015","unstructured":"Gadaleta RM, Cariello M, Sabba C, Moschetta A . Tissue-specific actions of FXR in metabolism and cancer. Biochim Biophys Acta 2015; 1851: 30\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"BFaps2016119_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bcp.2004.05.021","volume":"68","author":"C Wang","year":"2004","unstructured":"Wang C, Zhang JX, Shen XL, Wan CK, Tse AK, Fong WF . Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem Pharmacol 2004; 68: 843\u201355.","journal-title":"Biochem Pharmacol"},{"key":"BFaps2016119_CR19","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12272-012-1108-5","volume":"35","author":"HG Jin","year":"2012","unstructured":"Jin HG, Jin Q, Ryun Kim A, Choi H, Lee JH, Kim YS, et al. A new triterpenoid from Alisma orientale and their antibacterial effect. Arch Pharm Res 2012; 35: 1919\u201326.","journal-title":"Arch Pharm Res"},{"key":"BFaps2016119_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1055\/s-2006-947178","volume":"72","author":"ZY Jiang","year":"2006","unstructured":"Jiang ZY, Zhang XM, Zhang FX, Liu N, Zhao F, Zhou J, et al. A new triterpene and anti-hepatitis B virus active compounds from Alisma orientalis. Planta Med 2006; 72: 951\u20134.","journal-title":"Planta Med"},{"key":"BFaps2016119_CR21","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.3748\/wjg.15.2870","volume":"15","author":"YH Xu","year":"2009","unstructured":"Xu YH, Zhao LJ, Li Y . Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases\/Akt signaling pathways. World J Gastroenterol 2009; 15: 2870\u20137.","journal-title":"World J Gastroenterol"},{"key":"BFaps2016119_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.canlet.2005.02.011","volume":"231","author":"YT Huang","year":"2006","unstructured":"Huang YT, Huang DM, Chueh SC, Teng CM, Guh JH . Alisol B acetate, a triterpene from Alismatis rhizoma, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells. Cancer Lett 2006; 231: 270\u20138.","journal-title":"Cancer Lett"},{"key":"BFaps2016119_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.phymed.2016.04.003","volume":"23","author":"LL Zhang","year":"2016","unstructured":"Zhang LL, Xu YL, Tang ZH, Xu XH, Chen X, Li T, et al. Effects of alisol B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. Phytomedicine 2016; 23: 800\u20139.","journal-title":"Phytomedicine"},{"key":"BFaps2016119_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/BF02977323","volume":"30","author":"JM Hur","year":"2007","unstructured":"Hur JM, Choi JW, Park JC . Effects of methanol extract of Alisma orientale rhizome and its major component, alisol B 23-acetate, on hepatic drug metabolizing enzymes in rats treated with bromobenzene. Arch Pharm Res 2007; 30: 1543\u20139.","journal-title":"Arch Pharm Res"},{"key":"BFaps2016119_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bcp.2014.09.009","volume":"92","author":"Q Meng","year":"2014","unstructured":"Meng Q, Chen X, Wang C, Liu Q, Sun H, Sun P, et al. Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochem Pharmacol 2014; 92: 289\u201398.","journal-title":"Biochem Pharmacol"},{"key":"BFaps2016119_CR26","first-page":"913","volume":"17","author":"JE Klaunig","year":"1981","unstructured":"Klaunig JE, Goldblatt PJ, Hinton DE, Lipsky MM, Chacko J, Trump BF . Mouse liver cell culture. I. Hepatocyte isolation. In Vitro 1981; 17: 913\u201325.","journal-title":"I. Hepatocyte isolation. In Vitro"},{"key":"BFaps2016119_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0959-9673.2006.00465.x","volume":"87","author":"QM Anstee","year":"2006","unstructured":"Anstee QM, Goldin RD . Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1\u201316.","journal-title":"Int J Exp Pathol"},{"key":"BFaps2016119_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40265-015-0437-3","volume":"75","author":"C Filozof","year":"2015","unstructured":"Filozof C, Goldstein BJ, Williams RN, Sanyal A . Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 2015; 75: 1373\u201392.","journal-title":"Drugs"},{"key":"BFaps2016119_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574\u2013582.e571.","journal-title":"Gastroenterology"},{"key":"BFaps2016119_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956\u201365.","journal-title":"Lancet"},{"key":"BFaps2016119_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","volume":"51","author":"S Zhang","year":"2009","unstructured":"Zhang S, Wang J, Liu Q, Harnish DC . Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009; 51: 380\u20138.","journal-title":"J Hepatol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2016119","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2016119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2016119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:33:47Z","timestamp":1684413227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2016119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFaps2016119"],"URL":"https:\/\/doi.org\/10.1038\/aps.2016.119","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]},"assertion":[{"value":"5 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}